Takeaway

• Copanlisib-rituximab combo demonstrated superior efficacy to rituximab monotherapy, with a 48% reduction in the risk of disease progression/death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL) and is a new treatment option in these population.
• Improvements seen across all iNHL subtypes; manageable safety profile.

Why this matters

• Clinical benefits...